Which of the following is NOT a key point for gentamicin therapy?

• A. Gentamicin should be dosed using actual body weight
• B. Gentamicin should not be given in patients with Myasthenia Gravis
• C. Peak and trough levels of Gentamicin should be taken if a patient is taking more than 1 dose
• D. There is risk of nephrotoxicity and ototoxicity when using Gentamicin

Answer: (A)

Gentamicin has a narrow therapeutic window, so dosing and monitoring are focused on delivering enough drug to be effective while minimizing the risk of kidney and ear toxicity. Dosing by weight is common, but you shouldn’t rely on actual body weight in every patient—especially when obesity is present. In such cases, using ideal body weight or an adjusted body weight helps tailor the dose and interval to avoid overdosing and toxicity. That nuance is why simply stating that dosing should be based on actual body weight isn’t the best guideline. Other important aspects include avoiding gentamicin in patients with myasthenia gravis because aminoglycosides can worsen neuromuscular weakness, and measuring peak and trough levels when more than one dose is given to ensure the drug exposure stays within the therapeutic range. Plus, the known risks of nephrotoxicity and ototoxicity underscore the need for careful monitoring.